|Day Low/High||105.58 / 106.38|
|52 Wk Low/High||73.69 / 105.92|
INDIANAPOLIS, Aug. 14, 2018 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced that its subsidiary, Elanco Animal Health Incorporated, has priced a private offering of $2.
The weekly breakout is pretty impressive on the charts, so let's take a look.
The humanization of pets theme is driving outstanding earnings and share price growth for these 4 names.
INDIANAPOLIS, Aug. 2, 2018 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced that its subsidiary, Elanco Animal Health, has filed a registration statement with the U.
Investors may have been betting that the 'drug pricing war' was a non-event and that the upcoming earnings cycle would show continued growth and profitability in the healthcare sector.
We are bringing AMGN out of the Bullpen and into the portfolio.
Starting today, people can dial (833) 808-1234 to access potential cost savings on Lilly insulins
We are looking at today's rotation as an opportunity to pick up a high-quality name at a discount.
This market clearly has no clue what to buy, with strong GDP growth but challenging trade dynamics and the Facebook and Twitter bombs last week.
Extension of research collaboration focused on enhancing and speeding the process of bringing new and advanced treatments to cancer patients
The most recent short interest data was recently released for the 07/13/2018 settlement date, and Lilly (Eli) & Co is the #187 most shorted of the S&P 500 components, based on 4.67 "days to cover." There are a number of ways to look at short data, but one metric that we find particularly useful is the "days to cover" because it considers both the total shares short and the average daily volume of shares typically traded. The number of shares short is then divided by the average daily volume, to express the total number of trading days it would take to close out all of the open short positions if every share traded represented a short position being closed.
Top pharmaceutical companies are paving the way to a cure for Alzheimer's, a degenerative disease that is affecting millions around the world.
The biotech giant will present detailed results of its mid-stage trials of BAN2401 at the Alzheimer's Association International Conference in Chicago.
The Dow ended higher, breaking a 3-day skid, while the Nasdaq rebounded to end little changed after hitting a record high earlier.
Harley-Davidson, Verizon and other big hitters also reported earnings before Tuesday's opening bell.
The Indianapolis-based pharmaceutical giant unveils second-quarter results that surpass analysts' top- and bottom-line estimates.
Here are some options strategies for this FANG name into tomorrow's report.
U.S. stock futures rise on Tuesday, with solid corporate earnings boosting shares on Wall Street; Alphabet is set to open at a record high after the parent of Google posts a significant earnings beat; AT&T and Verizon highlight Tuesday's earnings calendar.
- Second-quarter 2018 revenue increased 9 percent, driven primarily by the increased demand for new pharmaceutical products, while operating expenses declined.
INDIANAPOLIS, July 24, 2018 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced that the company has completed its strategic review of Elanco Animal Health, and will file a registration statement in the coming weeks with the U.
We raised our price targets on four positions after their latest earnings reports.
We are taking a win, closing our LLY position and minimizing risk just a few days before it reports second-quarter earnings.
INDIANAPOLIS, July 20, 2018 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced that new results from a number of studies across the company's Alzheimer's disease pipeline will be presented at the Alzheimer's Association International...
INDIANAPOLIS, July 19, 2018 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) and Incyte Corporation (NASDAQ: INCY) announced today that results of a global systemic lupus erythematosus (SLE) Phase 2 study for baricitinib were published by The Lancet.
- Study supports long-term cardiovascular safety of Tradjenta® (linagliptin) in adults with type 2 diabetes
INDIANAPOLIS, July 19, 2018 /PRNewswire/ -- The U.S.
We're trimming the position at our highest sale price to date.
Sign up to get started or log in to see your watchlist.
Enter a symbol above to add it to your watchlist.
A confirmation email has been sent to the address provided during registration. Please click on the appropriate link to confirm your email address.